Academia-Industry Partnerships: Are we ready for new models of partnership?: The point of view of the EORTC, an academic clinical cancer research organisation

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 1-7

  Lacombe, Denis ^a   Burock, Susen ^a   Meunier, Françoise ^a  

^a EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEFITINIB; IMATINIB; TIRAPAZAMINE; VATALANIB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; COLORECTAL CANCER; COMPARATIVE STUDY; CONFLICT OF INTEREST; DRUG INDUSTRY; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY CONTROL;

ACADEMIC MEDICAL CENTERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS;

EID: 84871447346     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.09.027     Document Type: Article

References (29)

1. M. Senior, and E.F. Licking Back to school: big pharmas test new models for tapping academia In Vivo 29 2 2011 22 28
2. K.A. Getz, and J.R. Vogel Successful outsourcing: tracking global CRO usage Appl Clin Trials 17 18 2009 42 50
3. H.E. Glass, and P. Miller How much are CROs actually used Suppl Appl Clin Trials 2011 46 50
4. B.J. Druker, M. Talpaz, and D.J. Resta Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 14 2001 1031 1037 (Pubitemid 32267972)
5. J. Verweij, P.G. Casali, and J. Zalcberg Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 9440 2004 1127 1134 (Pubitemid 39296599)
6. M. Goldman Public-private partnerships need honest brokering Nat Med 18 3 2012 341
7. D.M. Cain, G. Loewenstein, and D.A. Moore When sunlight fails to disinfect: understanding the perverse effects of disclosing conflicts of interest J Consum Res 37 5 2012 836 857
8. D.M. Cain, G. Loewenstein, and D.A. Moore The dirt on coming clean: perverse effects of disclosing conflicts of interest J Legal Stud 34 1 2012 1 25
9. G. Loewenstein, S. Sah, and D.M. Cain The unintended consequences of conflict of interest disclosure JAMA 307 7 2012 669 670
10. J. Lexchin, L.A. Bero, B. Djulbegovic, and O. Clark Pharmaceutical industry sponsorship and research outcome and quality: systematic review BMJ 326 7400 2003 1167 1170 (Pubitemid 36649048)
11. S. Sismondo Pharmaceutical company funding and its consequences: a qualitative systematic review Contemp Clin Trials 29 2 2008 109 113 (Pubitemid 351248768)
12. J.E. Bekelman, Y. Li, and C.P. Gross Scope and impact of financial conflicts of interest in biomedical research: a systematic review JAMA 289 4 2003 454 465 (Pubitemid 36119966)
13. C.S. Perlis, M. Harwood, and R.H. Perlis Extent and impact of industry sponsorship conflicts of interest in dermatology research J Am Acad Dermatol 52 6 2005 967 971 (Pubitemid 40732534)
14. R.H. Perlis, C.S. Perlis, Y. Wu, C. Hwang, M. Joseph, and A.A. Nierenberg Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry Am J Psychiatry 162 10 2005 1957 1960 (Pubitemid 41428627)
15. L.S. Friedman, and E.D. Richter Relationship between conflicts of interest and research results J Gen Intern Med 19 1 2004 51 56 (Pubitemid 38221951)
16. R.M. Califf, D.A. Zarin, J.M. Kramer, R.E. Sherman, L.H. Aberle, and A. Tasneem Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010 JAMA 307 17 2012 1838 1847
17. R. Hemmings, and S. Day Regulatory perspectives on data safety monitoring boards: protecting the integrity of data Drug Saf 27 1 2004 1 6 (Pubitemid 38186934)
18. E.L. Korn, B. Freidlin, and M. Mooney Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005 J Clin Oncol 27 10 2009 1712 1721
19. H.G. Eichler, E. Abadie, A. Breckenridge, H. Leufkens, and G. Rasi Open clinical trial data for all? A view from regulators PLoS Med 9 4 2012 e1001202
20. B. Morgan, A.L. Thomas, and J. Drevs Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies J Clin Oncol 21 21 2003 3955 3964 (Pubitemid 46606209)
21. K. Mross, J. Drevs, and M. Muller Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours Eur J Cancer 41 9 2005 1291 1299 (Pubitemid 40813005)
22. E. Van Cutsem, E. Bajetta, and J. Valle Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma J Clin Oncol 29 15 2011 2004 2010
23. J.R. Hecht, T. Trarbach, and J.D. Hainsworth Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma J Clin Oncol 29 15 2011 1997 2003
24. A.F. Sobrero, and P. Bruzzi Vatalanib in advanced colorectal cancer: two studies with identical results J Clin Oncol 29 15 2011 1938 1940
25. M. Piccart, A. Goldhirsch, and W. Wood Keeping faith with trial volunteers Nature 446 7132 2007 137 138
26. J.P. Cohen Overcoming regulatory and economic challenges facing pharmacogenomics Nat Biotechnol 29 6 2012 751 756
27. L.J. Peters, B. O'Sullivan, and J. Giralt Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 J Clin Oncol 28 18 2010 2996 3001
28. J.G. Gaultney, E. Sanhueza, J.J. Janssen, W.K. Redekop, and C.A. Uyl-de Groot Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia Pharmacogenomics 12 3 2011 411 421
29. N.A. Goldenberg, A.C. Spyropoulos, and J.L. Halperin Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO model Blood 117 7 2011 2089 2092.